Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 36

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 1
Chunk 36
---
 acquired businesses - 40 basis points

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were favorably impacted by:

•First quarter 2024 acquisition-related fair value adjustment to inventory - 140 basis points

Depreciation and amortization of intangible assets increased as a percentage of sales during the three-month period ended March 28, 2025, primarily as a result of the decrease in sales and the impact of acquisitions.  

DIAGNOSTICS

The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Diagnostics Selected Financial Data

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$2,449 $2,527 Operating profit718 830 Depreciation100 97 Amortization of intangible assets48 48 Operating profit as a % of sales29.3 %32.8 %Depreciation as a % of sales4.1 %3.8 %Amortization as a % of sales2.0 %1.9 %

26

Sales Decline and Core Sales Decline 

% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales decline (GAAP)(3.0)%Impact of:Divestitures0.5 %Currency exchange rates 1.0 %Core sales decline (non-GAAP)(1.5)%

Price decreases, attributable to factors discussed below, in the segment of 0.5% negatively impacted the year-over-year change in sales during the three-month period ended March 28, 2025 and are reflected as a component of core sales above.

Total segment sales decreased 3.0% during the three-month period, primarily as a result of decreased core sales and to a lesser extent currency exchange rates and the impact of divestitures.  Overall segment core sales decline was driven primarily by decreased core sales in China attributable to the impact of China’s volume-based procurement program and healthcare reimbursement changes.  During the three-month period, core sales in the molecular diagnostics business declined year-over-year as decreased core sales of respiratory disease tests more than offset increased core sales in non-respiratory tests.  In the segment’s clinical diagnostics businesses core sales increased during the three-month period on a year